Research and Developments

Page 5 of 19« First...34567...10...Last »

December 11, 2015

Triple Therapy with Zeaxanthin Lessens Burden of Treatment for Wet AMD

Posted in: Health and Nutrition, Latest News, Research and Developments

As far back as 2007, triple therapy for wet (neovascular) age-related macular degeneration (AMD) was shown to be superior to mono therapy (intraocular injection of a single anti-VEGF drug).* And now, a study described in a recent online publication of the peer-reviewed monthly, International Journal of Retina and Vitreous, found that triple therapy supplemented with
read more »

December 10, 2015

Delayed Dark Adaptation Predicts Onset of Dry AMD

Posted in: Latest News, Research and Developments

A recent study* at the University of Alabama has found that measurement of the time it takes older adults’ eyes to adapt to the dark can predict onset of dry age-related macular degeneration (dAMD). Using a computerized dark adaptometer, 325 persons with healthy eyes were each subjected to a flash of light in one eye,
read more »

November 16, 2015

X-82 Oral Medication May Reduce Number of Intravitreal Injections for Wet AMD

Posted in: Latest News, Research and Developments

No cure yet exists for wet AMD, but three FDA-approved therapies are slowing the progress of wet AMD and reducing the amount of vision loss. These treatments are ranibizumab (Lucentis), aflibercept (Eylea), and off-label bevacizumab (Avastin). These medications are highly successful, but they must be injected directly into the eye, and the treatment often needs
read more »

November 16, 2015

Iluvien Similar to Anti-VEGF Drugs as Treatment for Diabetic Retinopathy

Posted in: Latest News, Research and Developments, Therapies, Treatments, and Procedures

On February 16, Charles C. Wykoff, MD, PhD, announced to the American Academy of Ophthalmology annual meeting that Iluviuan (fluocinolone acetonide) treatment, after 1.3 injections over 3 years in the FAME trials, “significantly reduced progression to prolific diabetic retinopathy from 31% to 17%, a similar reduction as observed with monthly anti-VEGF treatments.” Iluvian (Alimera Sciences)
read more »

October 27, 2015

RXI-109 May Reduce Retinal Scarring

Posted in: Latest News, Research and Developments

New drug silences connective tissue growth factor (CTGF), which plays a key role in tissue regeneration and repair. by Dan Roberts One of the most serious causes of vision loss is development of scar tissue on, in, or under the retina. People can develop retinal scarring from severe myopia, ocular histoplasmosis syndrome, and wet age-related
read more »

September 16, 2015

Diet, exercise, smoking habits, and genes interact to affect AMD risk

Posted in: Latest News, Research and Developments

NIH-funded study points to converging factors that drive disease-related inflammation People with a genetic predisposition for age-related macular degeneration (AMD) significantly increased their odds of developing the blinding eye disorder if they had a history of heavy smoking and consistently did not exercise or eat enough fruits and vegetables, according to an observational study of
read more »

September 8, 2015

Ocata’s Stem Cell Trials Entering Phase 2

Posted in: Latest News, Research and Developments

Results from First Cohort Expected in the Second Quarter of 2016 Acucela (formerly Ocata) has announced that the first patient has been enrolled in the company’s Phase 2 clinical trial using Ocata’s proprietary RPE cells in patients with atrophic (dry) age-related macular degeneration (AMD). The purpose of the trial is to evaluate safety and explore efficacy as compared
read more »

September 4, 2015

Long-term Treatment for Wet AMD Enters Phase 2 Trials

Posted in: Latest News, Research and Developments

Neurotech Pharmaceuticals, Inc. has announced that they have enrolled the first patient in their multicenter Phase 2 clinical trial of NT-503 Encapsulated Cell Therapy (ECT) for the long-term treatment of wet macular degeneration (AMD). NT-503 is a unique vascular endothelial growth factor (VEGF) receptor protein continuously produced by Neurotech’s versatile ECT implant. “This landmark proof-of-concept
read more »

July 19, 2015

Trash-Collecting Cells May Accelerate Retinitis Pigmentosa

Posted in: Latest News, Research and Developments

NIH research points to microglia as potential therapeutic target in retinitis pigmentosa Spider-like cells inside the brain, spinal cord and eye hunt for invaders, capturing and then devouring them. These cells, called microglia, often play a beneficial role by helping to clear trash and protect the central nervous system against infection. But a new study
read more »

June 24, 2015

Orcam Now Available in the U.S.

Posted in: Latest News, Research and Developments

In November 2013, an article appeared here about OrCam, a camera-based system which allows the visually impaired to both read and identify objects with a point of a finger. The device is a small camera connected by a thin cable to a portable computer in the wearer’s pocket. The system clips on to the wearer’s
read more »

Page 5 of 19« First...34567...10...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann